Cytosorbents Corp (OTCMKTS:CTSO)‘s stock had its “buy” rating reissued by Maxim Group in a research report issued on Wednesday. They currently have a $8.00 target price on the stock. Maxim Group’s target price would indicate a potential upside of 42.10% from the stock’s current price.
Separately, Brean Capital began coverage on shares of Cytosorbents Corp in a report on Tuesday. They set a “buy” rating and a $24.00 price objective for the company. Five analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $14.06.
Shares of Cytosorbents Corp (OTCMKTS:CTSO) opened at 5.63 on Wednesday. The stock’s 50 day moving average is $5.70 and its 200-day moving average is $4.79. Cytosorbents Corp has a one year low of $3.11 and a one year high of $8.10. The company’s market cap is $143.21 million.
Cytosorbents Corp (OTCMKTS:CTSO) last announced its earnings results on Tuesday, August 9th. The company reported ($0.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. The firm had revenue of $1.90 million for the quarter, compared to the consensus estimate of $2.18 million. Equities research analysts forecast that Cytosorbents Corp will post ($0.39) earnings per share for the current year.
Institutional investors have recently bought and sold shares of the company. Advisor Group Inc. acquired a new position in Cytosorbents Corp during the second quarter valued at $1,372,000. Raymond James & Associates increased its position in Cytosorbents Corp by 318.6% in the second quarter. Raymond James & Associates now owns 324,603 shares of the company’s stock valued at $1,477,000 after buying an additional 247,052 shares during the last quarter. Douglass Winthrop Advisors LLC acquired a new position in Cytosorbents Corp during the second quarter valued at $321,000. BlackRock Fund Advisors increased its position in Cytosorbents Corp by 39.3% in the second quarter. BlackRock Fund Advisors now owns 53,915 shares of the company’s stock valued at $245,000 after buying an additional 15,203 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Cytosorbents Corp by 1.0% in the second quarter. Vanguard Group Inc. now owns 537,707 shares of the company’s stock valued at $2,447,000 after buying an additional 5,446 shares during the last quarter.
About Cytosorbents Corp
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.